Tandem Diabetes Care Inc

Overview

Tandem Diabetes Care Inc (Tandem) is a medical device manufacturing company that designs and develops diabetic care products. The company's product portfolio includes t:slim X2 insulin pump, basal-IQ technology, software and applications, infusion sets and other pump accessories. It also provides product support services helping its clients to further customize their systems. The company distributes its products across various regions including Australia, Italy, New Zealand, and other Scandinavia regions (Sweden, Norway and Denmark). Tandem is headquartered in San Diego, California, the US.
Key Stats
Address
11075 Roselle St, SAN DIEGO, California
Headquarters

United States of America

Contact

1 858 3666900

No of Employees

1,500

Industry

Medical Equipment

Ticker Symbol & Exchange​

TNDM [NASD]

Revenue (2020)

$499 m

37.7% (2020 vs 2019)
Net Income (2020)

$-34 m

-37.4% (2020 vs 2019)
Net Profit Margin

-7 %

-0.9% (2020 vs 2019)
Market Cap *

$8,052 m

EPS *

$-0.6

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Tandem Diabetes Care IncEli Lilly and CoDexCom IncInsulet Corp
Key Information
Headquarters United States of America United States of America United States of America United States of America
Headquarter City SAN DIEGO INDIANAPOLIS SAN DIEGO ACTON
Headquarter State/Province California Indiana California Massachusetts
No. of Employees 1,500 35,000 5,500 1,900
Entity Type Public Public Public Public

Products & Services

Tandem operates as a medical device manufacturing company. The key products of the company include the following:

Products
  • t:slim X2 Insulin Pump
  • t:flex Insulin Pump
  • t:simulator Demo App
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • t:slim X2
  • t: Slim G4
  • t:Connect
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2020 Acquisitions/Mergers/Takeovers In June, the company acquired Sugarmate, a mobile application for people with diabetes.
2020 Contracts/Agreements In June, Tandem entered into an agreement with Tandem Diabetes Care to develop an integrated…
2020 Contracts/Agreements In July, the company and Medtronic entered into a patent cross-license agreement to focus on…
2016 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2015 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Sugarmate Inc
Tandem Diabetes Canada

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target

Jobs Overview

101

Active Jobs

46

Posted

46

Closed

Job Trends

Latest Jobs

Job title Company Country
Inside Sales Representative (Pump Therapy Sales Specialist) Tandem Diabetes Care Inc United States
Product Manager, Commercial Marketing Tandem Diabetes Care Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar